Strategic Partnerships Collaborations Pharmaceuticals has recent and notable partnerships, including a 2025 alliance with Bausch & Lomb to develop AI-driven oral drug candidates targeting ophthalmic conditions. This indicates openness to co-development and licensing models that sales teams can leverage to propose joint ventures, co-selling, or expanded AI-enabled drug discovery services.

AI Driven Pipeline The company emphasizes AI and ML for anti-cancer drug discovery and acetylcholinesterase inhibitor prediction, plus MegaTox capabilities. This suggests a ready-to-sell value proposition around AI software for target discovery and precision screening, with opportunities to upsell software licenses, SaaS access, and fee-for-service projects.

Grant Backing With $23.5M in grants secured since 2016, CPI demonstrates credibility and non-dilutive funding traction. Sales conversations can position CPI as a partner for grant-aligned projects, offering technical expertise, grant-ready project scoping, and potential collaboration on funded research initiatives for life sciences entities.

Geographic & Capacity Growth Expansion to Raleigh, NC in 2024 signals scalability and new operational capacity, including software development and business operations. This creates openings for regional services, on-site pilot programs, and co-located teams for faster delivery of AI-enabled discovery and clinical prep work.

Revenue & Services Mix A diversified model of software licensing, AI-enabled services, research collaborations, and fee-for-service offerings coupled with mid-market revenue scale positions CPI as a versatile partner. This enables cross-sell opportunities across software products, custom ML solutions, and contract research services to pharmaceutical and consumer product clients.